Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use
A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.
1. A hemostatic composition comprising:
a hemostatically effective amount of a hemostatic agent comprising:
a nanoparticle; and
a polyphosphate polymer attached to a surface of the nanoparticle; and
a protecting agent attached to the nanoparticle.
2. The composition of claim 1 , wherein the protecting agent comprises a polymer.
3. The composition of claim 1 , wherein the protecting agent comprises polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), poly(lactic-co-glycolic acid) (PLGA), polypropylene glycol, or a combination thereof.
4. The composition of claim 1 , wherein the protecting agent comprises poly(carboxybetaine), poly(sulfobetaine), poly(carboxybetaine methacrylate) (PCBMA), polyoxamers, a polypeptide, a biodegradable material, polylactonic acid or a derivative thereof, collagen, albumin, gelatin, hyaluronic acid, starch, cellulose, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulosephthalat, casein, dextrane, a polysaccharide, fibrinogen, poly(D,L-lactide), poly(D,L-lactide-co-glycolide), polyurethane, poly(ethylene vinyl acetate), silicone, an acrylic polymer, polyacrylic acid, polymethylacrylic acid, polyacrylcyanoacrylate, polyethylene, polypropylene, polyamide, poly(ester urethane), poly(ether urethane), poly(ester urea), a polyether, polyethylene oxide, polypropylene oxide, a triblock copolymer comprising hydrophobic polypropylene oxide (PPO) and hydrophilic polyethylene oxide (PEO) arranged in a PEO-PPO-PEO manner, polytetramethylene glycol, a vinyl polymer, polyvinylpyrrolidone, poly(vinyl alcohol), poly(vinylacetatephthalate), parylene, poly(hydroxybutylate), poly(alkyl carbonate), poly(orthoester), polyester, poly(hydroxyvaleric acid), polydioxanone, poly(ethylene terephthalate), poly(malic acid), poly(tartronic acid), polyanhydrides, polyphosphohazene, or a combination thereof.
5. The composition of claim 1 , wherein the protecting agent comprises a polyethylene glycol polymer.
6. The composition of claim 5 , wherein the polyethylene glycol polymer has a molecular mass ranging from 1000 Da to 20,000 Da.
7. The composition of claim 1 , wherein the protecting agent is substantially unreactive in a body.
8. The composition of claim 1 , wherein the protecting agent does not cause a coagulation cascade.
9. The composition of claim 1 , wherein the protecting agent reduces or inhibits the hemostatic activity of the hemostatic agent while attached to the nanoparticle.
10. The composition of claim 1 , wherein the hemostatic agent has substantially no hemostatic activity while the protecting agent is attached.
11. The composition of claim 1 , wherein the protecting agent prevents substantial interaction between the polyphosphate polymer and elements of a coagulation cascade.
12. The composition of claim 1 , wherein the protecting agent is attached to the nanoparticle through a phosphoramidate linkage.
13. The composition of claim 1 , wherein the protecting group is attached to the nanoparticle by a cleavable group.
14. The composition of claim 13 , wherein the protecting agent prevents substantial interaction between the polyphosphate polymer and elements of a coagulation cascade, and wherein cleavage of the cleavable group allows interaction between the polyphosphate polymer and elements of the coagulation cascade and allows the hemostatic agent to have hemostatic activity.
15. The composition of claim 13 , wherein the cleavable group is an enzymatically-cleavable group.
16. The composition of claim 15 , wherein the cleavable group can be cleaved by an enzyme involved in a coagulation cascade.
17. The composition of claim 16 , wherein the enzyme involved in the coagulation cascade is thrombin (Factor IIa), Factor Vila, Factor IXa, Factor Xa, FactorXia, Factor Xia, Factor XIIa, Factor XIIIa, a tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), activated protein C, or plasmin.
18. The composition of claim 15 , wherein the cleavable group can be cleaved by a protease enzyme.
19. The composition of claim 13 , wherein the cleavable group comprises an amide group and the cleavable group can be cleaved by a peptidase enzyme.
20. The composition of claim 19 , wherein the amide group is part of an amino acid residue.
21. The composition of claim 13 , wherein the cleavable group is configured to selectively cleave at a desired location within a body.
22. The composition of claim 21 , wherein the desired location is an internal hemorrhage site or an external hemorrhage site.